T. Rowe Price Associates’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $348K | Sell |
|
|||||
|
2025
Q3 | $283K | Buy |
|
|||||
|
2025
Q2 | $288K | Hold |
|
|||||
|
2025
Q1 | $239K | Buy |
|
|||||
|
2024
Q4 | $248K | Buy |
|
|||||
|
2024
Q3 | $235K | Buy |
|
|||||
|
2024
Q2 | $221K | Sell |
|
|||||
|
2024
Q1 | $272K | Buy |
|
|||||
|
2023
Q4 | $169K | Buy |
|
|||||
|
2023
Q3 | $127K | Buy |
|
|||||
|
2023
Q2 | $155K | Buy |
|
|||||
|
2023
Q1 | $134K | Buy |
|
|||||
|
2022
Q4 | $139K | Buy |
|
|||||
|
2022
Q3 | $158K | Buy |
|
|||||
|
2022
Q2 | $164K | Sell |
|
|||||
|
2022
Q1 | $3.22M | Buy |
|
|||||
|
2021
Q4 | $3.69M | Sell |
|
|||||
|
2021
Q3 | $52.4M | Sell |
|
|||||
|
2021
Q2 | $36.3M | Sell |
|
|||||
|
2021
Q1 | $154M | Buy |
|
|||||
|
2020
Q4 | $102M | Buy |
|